Qiagen reported better-than-expected Q4 results. Double-digit growth in the non-Covid-19 product group was however overshadowed by the substantial decline in Covid-19 sales. Moreover, the 2023 guidance assumes a further material decline in Covid-19 sales. However, with the lynchpin segment, i.e. non-Covid-19 products, again guided to clock healthy double-digit growth in 2023, and various innovation and bolt-on initiatives, Qiagen remains an attractive sector bet – which may also garner new M&A i ....